Texas Medicaid GLP-1 Coverage (2026): What's Covered, STAR+PLUS PA Pathway, and How to Appeal a Denial

Texas Medicaid covers Ozempic, Trulicity, Victoza, and Byetta as Preferred drugs for type 2 diabetes on the January 30, 2026 Vendor Drug Program (VDP) Preferred Drug List, with prior authorization and a 365-day approval period. Texas does NOT cover Wegovy or Saxenda for chronic weight management — both are explicitly labeled “Non-Covered Benefit” in the only Texas-specific primary-source coverage table that names them, the Superior HealthPlan provider notice of June 6, 2023. The legal rationale is the federal optional weight-loss-drug exclusion at 42 U.S.C. § 1396r-8(d)(2)(A), which permits states to decline Medicaid coverage of “agents when used for anorexia, weight loss, or weight gain.” Texas has elected to use it. Per the KFF Medicaid tracker (January 2026), only 13 state Medicaid programs cover GLP-1s for obesity; Texas is not among them. HB 2412 (89th Texas Legislature, 2025) would have mandated obesity-indication GLP-1 coverage but did not pass — historical context only.

Bottom line: what Texas Medicaid covers (and does not)

The single most consequential fact for any Texas Medicaid member or prescriber working a GLP-1 prescription:

• Type 2 diabetes-indicated GLP-1s (Ozempic, Trulicity, Victoza, Byetta) are covered with prior authorization as Preferred agents on the January 30, 2026 Texas Medicaid PDL.
• Mounjaro (tirzepatide for T2D) and Rybelsus (oral semaglutide for T2D) have historically been Non-Preferred; both are absent from the Jan 30, 2026 preferred-incretin section, consistent with that historical posture.
• Wegovy (semaglutide 2.4 mg for chronic weight management) and Saxenda (liraglutide 3 mg for chronic weight management) are explicitly Non-Covered Benefit for Texas Medicaid and CHIP per the Superior HealthPlan provider notice. The Jan 30, 2026 PDL Criteria Guide contains no entry for either drug — consistent with the Non-Covered Benefit determination.
• Zepbound (tirzepatide for chronic weight management or obstructive sleep apnea in obesity) is absent from the Jan 30, 2026 PDL Criteria Guide. Coverage status under any indication for 2024–2026 is not directly verified by a 2024+ Texas-specific primary source. We do not assert that Zepbound is or is not covered.
• Foundayo (orforglipron — Eli Lilly's oral GLP-1 brand) is a direct-to-consumer cash-pay product that does not bill insurance; PDL status is irrelevant to the Foundayo patient pathway.

The legal lever that lets Texas exclude weight-management GLP-1s is the federal optional weight-loss-drug exclusion in the Medicaid statute. The next section walks through it.

Why weight-loss GLP-1s are excluded under federal law

Federal Medicaid drug-coverage rules permit — but do not require — states to exclude certain enumerated categories of drugs from coverage. The category that matters for Wegovy, Saxenda, and Zepbound (when prescribed for chronic weight management) is at 42 U.S.C. § 1396r-8(d)(2)(A). Verbatim:

“Agents when used for anorexia, weight loss, or weight gain.”

This is one of seven enumerated optional-exclusion categories in the statute (others include fertility, cosmetic, cough & cold, prescription vitamins, smoking-cessation, and DESI less-than-effective drugs). The federal floor: states may decline Medicaid coverage of any drug when prescribed for one of these uses. The federal ceiling: states may elect to cover them anyway — nothing prohibits state coverage. The federal rule is permissive authority, not a federal mandate to exclude.

Texas has elected to use the optional exclusion for the weight-loss indication. The verbatim primary-source confirmation is the Superior HealthPlan provider notice (June 6, 2023):

“Although a majority are approved with the appropriate diagnosis of type 2 diabetes, obesity is also one of the top reasons for requesting the medication and is being denied as an excluded benefit.”

And from the same notice, framing how plan-level coverage is actually determined:

“Coverage is determined by formulary restrictions for Ambetter from Superior HealthPlan and Texas Vendor Drug Program for Medicaid and CHIP.”

The KFF January 2026 state-by-state Medicaid GLP-1 tracker corroborates this from a third-party-survey angle:

“Only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service arrangements” as of January 2026.

Texas is not among those 13 states per the KFF January 2026 tracker. (Hedging note: KFF is a third-party survey, not a primary source for Texas-specific policy. The primary-source evidence for Texas is the Acentra Jan 30, 2026 PDL Criteria Guide's absence of Wegovy/Saxenda entries plus the Superior HealthPlan 2023 verbatim coverage table.)

Drug-by-drug coverage status (Texas Medicaid)

Each row below cites either (a) the Acentra Jan 30, 2026 PDL Criteria Guide (the operational implementation of the state VDP PDL) or (b) the Superior HealthPlan June 6, 2023 provider notice — the only Texas-specific primary sources verifiable by direct fetch on 2026-05-09.

YMYL note on Zepbound: we do not claim Zepbound is covered by Texas Medicaid, and we do not claim it is excluded. Patients and prescribers seeking a determination should contact their managed-care plan member services line directly for a plan-specific PA inquiry. The same hedging applies to the Wegovy cardiovascular event-reduction indication (FDA approved March 2024) and the Wegovy MASH indication (FDA approved August 2025): the Texas VDP PA Criteria Guide as of January 30, 2026 does not address coverage of Wegovy under these non-weight-loss indications, and patients should expect plan-level clinical PA review on a case-by-case basis.

Verbatim PA criteria from the Acentra Jan 30, 2026 PDL Criteria Guide

For the four Preferred T2D-indicated GLP-1s (Ozempic, Trulicity, Victoza, Byetta), the prior-authorization gate is a class-level criterion in Section 62 (Hypoglycemics, Incretin Mimetics/Enhancers). Verbatim from page 287 of the 572-page guide:

“Hypoglycemics, Incretin Mimetics/Enhancers — Prior Authorization Criteria

1. Has the client failed a 14-day treatment trial with at least 1 preferred agent in the past medical and/or pharmacy claims history?
☐ Yes (Approve — 365 days)
☐ No (Go to #2)

2. †Is there a documented allergy or contraindication to preferred agents in this class?
☐ Yes (Approve — 365 days)
☐ No (Go to #3)

3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?
☐ Yes (Approve — 365 days)
☐ No (Deny)

† Specific PDL exceptions in reference to contraindications, adverse drug reactions, and drug ineffectiveness fall under the PDL criteria exception section and are located on page 1 of the PDL Criteria Guide in the Document Overview section.”

Three things to know about this PA logic:

1. Approval, when granted, is for 365 days. That is meaningfully longer than commercial-payer initial approval windows (Cigna IP0206 issues 8-month initial approvals for weight-management GLP-1s; Aetna 4774-C is 7-month). 365 days reduces the reauthorization friction.
2. The 14-day failed trial of a preferred agent is the primary gate. A patient asking for a Non-Preferred GLP-1 (e.g., Mounjaro, Rybelsus) generally must show prior medical/pharmacy claims for a Preferred agent (Ozempic, Trulicity, Victoza, or Byetta) for at least 14 days that did not produce adequate glycemic response. This is a step-therapy substitute — the state PDL prefers the Preferred agents on cost grounds (rebate dollars).
3. Contraindication / allergy / inefficacy exceptions are anchored in HB 3286 (88th Legislature, 2023). That law expanded the documented PDL-exception pathway. The Acentra guide's Document Overview section (pages 1–2) captures the verbatim Table 1 exceptions:

“Table 1:

- Treatment failure with preferred drugs within any subclass
- Contraindication to preferred drugs†
- Allergic reaction to preferred drugs†
- Treatment of stage-four advanced, metastatic cancer and associated conditions

HB 3286, Section 2, 88th Legislature, Regular Session, 2023, requires the Health and Human Services Commission (HHSC) to allow the additional exceptions on the Preferred Drug List.”

And the verbatim Table 2 contraindication / inefficacy framework:

“Table 2:

- Is contraindicated
- Will likely cause an adverse reaction or physical or mental harm to the recipient
- Is expected to be ineffective based on the known clinical characteristics of the recipient and the known characteristics of the prescription drug regimen
- The recipient previously discontinued taking the preferred drug at any point in their clinical history and for any length of time due to ineffectiveness, diminished effect, or adverse event(s)

These specific PDL exceptions referencing contraindications, adverse drug reactions, and drug ineffectiveness fall under the PDL exceptions listed in Table 1 and will be notated with ‘†’ on each prior authorization criteria question and logic diagram of each section.”

The practical implication: a patient who has documented ineffectiveness or intolerance of an Ozempic/Trulicity/Victoza trial — or whose prescriber is willing to attest in writing that a Preferred agent is “expected to be ineffective based on the known clinical characteristics of the recipient” — has a documented, statutorily-grounded pathway to a Non-Preferred T2D GLP-1.

Verbatim Superior HealthPlan 2023 Non-Covered Benefit notice for Wegovy and Saxenda

Superior HealthPlan is a Centene-owned Texas Medicaid + CHIP managed-care plan. Its June 6, 2023 provider notice is the only Texas-specific primary source that uses the exact phrase “Non-Covered Benefit” for Wegovy and Saxenda. The notice publishes a coverage table with the column header “Texas Medicaid Coverage” — those rows are reproduced below verbatim:

This is a 2023 plan-level snapshot. The Acentra Jan 30, 2026 PDL Criteria Guide's complete absence of any entry for Wegovy or Saxenda is consistent with the Non-Covered Benefit finding and is the strongest available primary-source claim for Texas Medicaid. We do not rely on third-party state-by-state survey aggregators that classify Texas as “partial coverage” for obesity-specific GLP-1s — that framing conflicts with both the Acentra Jan 30, 2026 PDL Criteria Guide and the Superior June 2023 verbatim coverage table, and the primary-source evidence supports a non-coverage finding for the weight-management indication.

Texas managed-care plans (STAR, STAR+PLUS, STAR Kids, STAR Health, CHIP)

Texas Medicaid is delivered to most enrollees through capitated managed-care plans, not fee-for-service. The major program lines:

• STAR — children, pregnant women, and non-disabled families.
• STAR+PLUS — adults age 21+ with disabilities and dual-eligible (Medicare + Medicaid) enrollees. STAR+PLUS is the program line where most of the chronic-condition adult Medicaid population sits.
• STAR Kids — children with disabilities and complex medical needs.
• STAR Health — children and youth in foster care.
• CHIP — Children's Health Insurance Program (separate from Medicaid; family-income-based).

The major Texas Medicaid + CHIP managed-care plans include Aetna Better Health of Texas, Wellpoint Texas (formerly Amerigroup), Molina Healthcare of Texas, Superior HealthPlan (Centene), and UnitedHealthcare Community Plan of Texas. The operational role of these plans for GLP-1 prescriptions is uniformly to defer to the state VDP PDL on the formulary side. Verbatim from the Superior HealthPlan provider page (verified 2026-05-09):

“Superior covers prescription medications as outlined by the Texas Medicaid and CHIP Vendor Drug Program (VDP), with some medications requiring prior authorization and clinical prior authorization edits or other limitations consistent with FDA recommendations.”

And the operational PA contact:

“For prior authorization of medications covered by the VDP, contact the contracted PBM at 1-866-768-7147.”

The implication for patients and prescribers: Texas Medicaid managed-care plans in the GLP-1 space follow the state VDP PDL — they do not publish independent preferred / non-preferred GLP-1 lists that diverge from the state PDL. The plan-level role is operational: receiving the PA fax, applying the same VDP criteria, and routing approvals/denials. We do not claim that any individual STAR+PLUS plan has stricter or looser GLP-1 PA than the VDP PDL, because no plan-specific primary source we could verify on 2026-05-09 supports that.

How to appeal a Texas Medicaid GLP-1 denial

If a Texas Medicaid managed-care plan denies a GLP-1 PA, members have a structured multi-step appeal pathway. The state-level framework involves three escalation levels:

1. Internal plan appeal. File within the deadline specified on the denial letter (typically 60 days from the date of the adverse benefit determination notice for managed-care plans; check the specific plan's Member Handbook). The appeal can be filed by the member, the prescribing provider acting on the member's behalf, or an authorized representative. Submit the written denial letter, the prescriber's Letter of Medical Necessity (LOMN) addressing the specific clause cited, and supporting clinical documentation.
2. State Fair Hearing through Texas HHSC. If the internal plan appeal is upheld (denial sustained), members have the right to request a State Fair Hearing through the Texas Health and Human Services Commission. The request typically must be filed within 120 days of the adverse internal-appeal decision (verify the current deadline on the plan's adverse-decision letter). State Fair Hearings are conducted by an HHSC hearings officer; the member can present testimony and documentary evidence.
3. External Review through an Independent Review Organization (IRO). Texas Medicaid managed-care plans participate in the external review process administered by the Texas Department of Insurance (TDI) for medical-necessity disputes. External review by an IRO provides a binding independent determination — the IRO's decision is binding on the plan if it overturns the denial. External review is free to the member; the plan pays for the IRO. The IRO request process varies by managed-care plan; the plan's adverse-decision letter must include the external review request instructions.

For the appeal mechanics that apply across payers — including what to include in a Letter of Medical Necessity, how to engage with the verbatim policy clause cited in the denial, and how to request a state-level external review — see our GLP-1 insurance dropped coverage appeal playbook. The four-phase appeal logic in that playbook applies directly to Texas Medicaid managed-care denials, with the state-level escalation through HHSC State Fair Hearing and TDI external review substituted for the commercial plan appeal pathway.

What an appeal cannot fix: if the denial is because the drug is a Non-Covered Benefit under the state PDL (e.g., Wegovy or Saxenda for chronic weight management), the appeal pathway will not produce coverage — the determination is policy-level, not clinical. Wegovy under the cardiovascular event-reduction indication or Saxenda under any non-weight-loss off-label indication may be a different clinical-PA conversation, but the article does not assume that pathway succeeds; outcomes are case-by-case and plan-specific.

What if you have T2D and need Mounjaro or Zepbound?

Two patient profiles surface here:

• T2D + Mounjaro request. Mounjaro (tirzepatide) for type 2 diabetes is Non-Preferred under Texas Medicaid (per Superior HealthPlan's 2023 plan-level data; absent from the Jan 30, 2026 PDL preferred-incretin section). The PA pathway is the same Section 62 logic: a 14-day failed trial of a Preferred agent (Ozempic, Trulicity, Victoza, or Byetta) OR a documented allergy/ contraindication to Preferred agents OR stage-4 advanced metastatic cancer indication. The 14-day failed-trial gate is the most common pathway. Document it in the prescriber's chart with the exact agent tried, the dose, the dates, and the clinical reason it was discontinued (e.g., GI intolerance with persistent vomiting, inadequate glycemic response after dose titration).
• T2D + Zepbound request. Zepbound is FDA-approved for chronic weight management and for obstructive sleep apnea in obesity — not for type 2 diabetes. A T2D patient asking for Zepbound is asking for off-label diabetes use of a chronic-weight-management drug, which Texas Medicaid will generally not cover. The on-label tirzepatide brand for T2D is Mounjaro. Patients who want tirzepatide for T2D should be prescribed Mounjaro, which routes through the Section 62 PA logic above.
• Obesity + Zepbound request. Zepbound for chronic weight management is in the same federal optional-exclusion category as Wegovy and Saxenda. Coverage status is not directly verified for Texas Medicaid in any 2024+ Texas-specific primary source available on 2026-05-09. The Acentra Jan 30, 2026 PDL Criteria Guide does not list Zepbound. Patients should contact their managed-care plan member services line for a plan-specific determination. Do not assume coverage; do not assume exclusion; the article makes no claim either way.

What about HB 2412?

Texas legislators introduced HB 2412 in the 89th Regular Session (2025) — “Relating to health benefit plan coverage of certain medications used for the treatment of obesity.” The bill would have mandated that health benefit plans, Texas state-employee plans, and the Texas Medicaid program cover GLP-1 receptor agonists for obesity when prescribed in compliance with FDA-approved indications. The proposed effective date if passed was September 1, 2025, with the coverage requirement applying to plans on or after January 1, 2026.

HB 2412 did NOT advance to enactment. Texas Medicaid is not currently under a state-statutory mandate to cover anti-obesity GLP-1s. The federal optional weight-loss-drug exclusion at 42 U.S.C. § 1396r-8(d)(2)(A) remains the operative legal authority for the Texas exclusion of Wegovy and Saxenda for chronic weight management.

HB 2412 is included here as historical context. The article does not represent it as enacted policy or as a coverage pathway patients can rely on. Future legislative sessions may revisit the question, but as of 2026-05-09 the bill is dead and the Texas Medicaid coverage framework is unchanged from the Superior 2023 verbatim Texas Medicaid Coverage table.

For patients without coverage: cash-pay options

Patients without Texas Medicaid coverage of a chronic-weight- management GLP-1 — and patients on Texas Medicaid for whom the PA pathway will not succeed — have several manufacturer- and retailer-direct cash-pay options that do not require insurance. Verified 2026-05-09:

• NovoCare Pharmacy (Wegovy). Novo Nordisk self-pay program. Wegovy 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg single-dose pens at $299/month for cash- pay patients who do not have insurance or whose insurance does not cover Wegovy. Order through novocare.com.
• LillyDirect Self Pay Pharmacy (Zepbound). Eli Lilly direct-to-consumer vials. Zepbound 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg vials at $299–$449/month depending on dose strength. Ordered through lillydirect.com.
• LillyDirect / Amazon Pharmacy (Foundayo). Eli Lilly oral GLP-1 (orforglipron tablets) at $149/month. Foundayo is the direct-to-consumer cash-pay brand and does not bill insurance — Texas Medicaid PDL status is not relevant to the Foundayo pathway.
• GoodRx and other discount-card programs. For T2D-indicated GLP-1s (Ozempic, Trulicity, Victoza), GoodRx coupons are a cash-pay fallback when Medicaid PA is denied. Pricing varies by zip code and pharmacy; check goodrx.com for the patient's specific medication and local pharmacy.
• Compounded options. Compounded semaglutide and compounded tirzepatide from licensed 503A pharmacies run roughly $99–$300/month in the cash-pay market. Important regulatory caveat: the FDA enforcement-discretion period for compounded tirzepatide ended October 2024, and for compounded semaglutide ended February 2025. Compounding activity for these molecules is in a regulatory grey zone. The article does not name specific compounding pharmacies or telehealth vendors. Patients considering compounded options should verify the pharmacy's NPI, state board licensure, and product- quality testing before ordering.

For more on the manufacturer-direct cash-pay landscape and the relationship between insurance pathways and self-pay options, see our GLP-1 insurance coverage across Medicare, Medicaid, and commercial deep-dive.

For patients on disability/SSI: Medicare Part D + STAR+PLUS coordination

Most adult Texas Medicaid enrollees with disabilities and most senior Texas Medicaid enrollees are dual-eligible — they have both Medicare (the federal age-65+ / disability program) and Medicaid (the federal-state low-income program). For dual-eligible Texas residents, prescription drug coverage flows through Medicare Part D (the Medicare prescription drug benefit) NOT through Texas Medicaid VDP.

This matters for GLP-1 coverage because Medicare Part D has its own statutory exclusion of weight-loss drugs at Social Security Act § 1860D-2(e)(2)(A), and its own framework for covering GLP-1s under non-weight-loss indications:

• Wegovy under the cardiovascular event-reduction indication (FDA approved March 2024 for adults with established cardiovascular disease and obesity/overweight) is Part D-coverable on most Medicare Advantage Prescription Drug (MA-PD) and standalone Part D plans because the indication is non-weight-loss. PA criteria apply.
• Zepbound under the obstructive sleep apnea (OSA) indication (FDA approved December 2024 for moderate-to-severe OSA in obese adults) is similarly Part D-coverable on most MA-PD plans because the indication is non-weight-loss. PA criteria apply.
• Wegovy, Zepbound, Saxenda, and Foundayo under the chronic-weight-management indication are statutorily excluded from Medicare Part D coverage. Patients in this scenario have no Part D pathway to the weight-loss indication.
• T2D-indicated GLP-1s (Ozempic, Trulicity, Victoza, Mounjaro for T2D, Rybelsus for T2D) are Part D-coverable with PA on most MA-PD plans for the type 2 diabetes indication.

For dual-eligible Texas residents, the practical sequence is: check the Medicare Part D plan's formulary first, not the Texas VDP PDL. The Medicare Part D prescription is the operative coverage source. Texas Medicaid covers the Medicare Part D copay (Medicare Savings Program / Qualified Medicare Beneficiary status) but does not directly pay the prescription. For verbatim payer-policy criteria on the commercial-side analogs, see our Cigna GLP-1 prior-authorization guide and Aetna GLP-1 prior-authorization guide — both Cigna and Aetna operate Medicare Advantage plans in Texas with similar GLP-1 PA structures.

Bottom line

Texas Medicaid covers four GLP-1 receptor agonists (Ozempic, Trulicity, Victoza, Byetta) as Preferred drugs for type 2 diabetes on the January 30, 2026 PDL Criteria Guide, with prior authorization and a 365-day approval. The PA gate is a 14-day failed trial of a Preferred agent OR a documented allergy/contraindication OR a stage-4 advanced metastatic cancer indication. Mounjaro and Rybelsus are Non-Preferred and route through the same logic with the Preferred-trial step.

Texas Medicaid does NOT cover Wegovy or Saxenda for chronic weight management — both are explicitly “Non-Covered Benefit” per the Superior HealthPlan June 2023 verbatim Texas Medicaid Coverage table, and both are absent from the Acentra Jan 30, 2026 PDL Criteria Guide. The legal rationale is the federal optional weight-loss-drug exclusion at 42 U.S.C. § 1396r-8(d)(2)(A), which Texas has elected to use. Zepbound coverage status is not directly verified by any 2024+ Texas-specific primary source as of 2026-05-09; the article makes no claim either way and refers patients to their plan member services line. HB 2412 (89th Texas Legislature, 2025) would have mandated obesity-indication GLP-1 coverage but did not pass.

Patients without coverage have manufacturer-direct cash-pay options (NovoCare Wegovy $299/month, LillyDirect Zepbound $299–$449/month, Foundayo $149/month) and a regulatory grey-zone compounded GLP-1 channel that we do not vendor-name. Dual-eligible Texas residents flow through Medicare Part D, not Texas VDP — which has its own framework allowing Wegovy under the cardiovascular indication and Zepbound under the OSA indication, with weight-loss-only Wegovy/Zepbound/ Saxenda/Foundayo statutorily excluded from Part D.

The article makes no clinical recommendation, no plan- specific coverage promise, and no appeal-success guarantee. Coverage and PA outcomes vary by individual clinical facts, managed-care plan, and PDL revision cycle. Readers should contact their plan member services line, their prescriber, or a Medicaid-experienced benefits navigator for an authoritative determination on any specific case.

Related research

• Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + the January 2026 Wegovy MACE/MASH carve-back-in — companion 50-state Medicaid series article. Ohio is the most explicitly anchored non-coverage state in the series: triple- anchored by federal statute, OAC 5160-9-03(B)(1) state regulation, AND the Gainwell SPBM real-time claim gate (Nov 7, 2025 notice naming “weight loss” as non-covered). Ohio's Gainwell SPBM structure (all managed-care + FFS through one PBM) is more centralized than Texas's STAR+PLUS plan-level model. Ohio opened a Wegovy MACE + MASH PA pathway effective January 7, 2026; Texas has no equivalent non-obesity Wegovy pathway.
• Florida Medicaid GLP-1 coverage (2026): the silent exclusion — companion 50-state Medicaid series article. Florida is the silent-exclusion counterpart to Texas's explicit- non-coverage model: Superior HealthPlan's June 2023 provider notice names Wegovy and Saxenda as “Non-Covered Benefit” directly — a verbatim label Florida Medicaid's AHCA has never issued. Florida's exclusion is established by PDL operational absence (Wegovy / Zepbound / Saxenda absent from the April 1, 2026 AHCA PDL and March 12, 2026 GLP-1 Criteria PDF). Both states use the federal optional weight-loss exclusion at 42 USC § 1396r-8(d)(2)(A); the evidential pathway is the key structural difference.
• New York Medicaid (NYRx) GLP-1 coverage + Wegovy MACE pathway (2026) — companion 50-state Medicaid series article. New York's NYRx carve-out (April 1, 2023) is structurally opposite Texas's plan-level managed-care PDL system: NYRx consolidates all mainstream MMC, HARP, and HIV-SNP outpatient pharmacy PA into a single statewide PBM (Prime Therapeutics State Government Solutions), so plan-level divergence is impossible. Weight-loss exclusion is triple-anchored by federal statute (42 USC § 1396r-8(d)(2)(A)), state regulation (18 NYCRR § 505.3(g)(3)), and explicit NYRx contractor documentation naming Ozempic / Wegovy / Mounjaro by brand. Wegovy MACE pathway with stricter-than-FDA-label BMI ≥ 40 + lifetime cap of 2 attempts.
• California Medi-Cal GLP-1 coverage (2026): the state reversal that removed Wegovy + Zepbound for weight loss — companion 50-state series article. California reversed course on GLP-1 obesity coverage effective January 1, 2026 (Wegovy, Zepbound, Saxenda removed from the Medi-Cal Rx CDL for weight loss); Wegovy was added back April 1, 2026 for noncirrhotic MASH only (ICD-10-CM K76.0 / K75.8 required). California's statewide Medi-Cal Rx carve-out makes plan-level divergence structurally impossible — a structurally different system from Texas's STAR+PLUS managed-care model.
• GLP-1 insurance coverage across Medicare, Medicaid, and commercial — the federal-state coverage framework, KFF state tracker, and how Wegovy/Zepbound/Foundayo actually flow through Medicare Part D and state Medicaid programs.
• GLP-1 insurance dropped coverage appeal playbook — the four-phase appeal logic (internal, external, cash-pay bridge, switch-brand) that applies directly to Texas Medicaid managed-care denials with state-level escalation substitutions.
• Cigna GLP-1 prior-authorization guide — verbatim IP0206 / CNF 684 / CNF 360 coverage policies for the Cigna commercial-side analog (and Cigna's Texas Medicare Advantage plans).
• Aetna GLP-1 prior-authorization guide — verbatim 4774-C / 6947-C / 1227-C coverage policies for the Aetna commercial-side analog (and Aetna Better Health of Texas).
• Wegovy alternatives 2026 — for patients whose Texas Medicaid Wegovy request was denied as Non-Covered Benefit and who are evaluating Zepbound, Foundayo, Saxenda, and the cash-pay landscape.
• Zepbound alternatives 2026 — formulary-displaced patient profiles and the realistic alternatives when Zepbound is unavailable.
• Saxenda (liraglutide) evidence + Teva generic 2026 — the SCALE trial data and the August 2025 Teva generic liraglutide approval (the first FDA-approved generic GLP-1 for chronic weight management).
• Georgia Medicaid GLP-1 coverage (2026): dual-level operational non-coverage — Statewide PDL omission + Peach State Health Plan explicit exclusion — companion 50-state series article. Texas and Georgia both anchor on the federal optional exclusion (42 USC § 1396r-8(d)(2)(A)) and both use CMO member-facing language to reinforce the state PDL exclusion: Texas's Superior HealthPlan June 2023 provider notice names Wegovy and Saxenda as “Non-Covered Benefit”; Georgia's Peach State Health Plan Member PDL names “Drugs prescribed for weight loss” as categorically excluded from the PDL and the 72-hour emergency supply. The key structural difference: Texas also has a state Administrative Code hook (TX Admin. Code Title 1 § 354.1832); Georgia's CMO explicit language exists alongside a [VERIFIED ABSENCE] of any state regulation, making Georgia's exclusion more administratively flexible and more reversible.
• GLP-1 prior-authorization letter generator — embeds verbatim payer-policy criteria into a Letter of Medical Necessity template usable for Texas Medicaid PA submissions and managed-care appeals.